Elsevier Ltd, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom

Elsevier Ltd, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom's articles

  1. Pharmaceuticals and Drug Development

UK antibiotic subscription model key to supporting antibiotic investment

For the world to meet the health challenge posed by increasing antimicrobial resistance (AMR), new ways must be found to overcome the market failure that holds back the development of new antibiotics.  Critical to this is greater understanding of the factors needed to persuade investors to support research and development (R&D) efforts. The latest report […]
Written by
  1. Pharmaceuticals and Drug Development

15 years of Op Pangea: over 25 million illegally traded medicines and devices seized in the UK valued at more than £84m

This year marks 15 years since the Medicines and Healthcare products Regulatory Agency (MHRA) launched Operation Pangea, an initiative cracking down on medicines crime. Pangea is now coordinated by Interpol, and the MHRA’s Criminal Enforcement Unit (CEU) joined 89 countries for this year’s operation. Working with law enforcement partners, the CEU seized over two million […]
Written by
  1. Pharmaceuticals and Drug Development

How AI is Transforming Drug Discovery: Bio-IT World Europe Participants to Share Groundbreaking Advances 29-30 November in London

LONDON, Nov. 6, 2023 — The life sciences profession is in the midst of a profound transformation, guided by the revolutionary force of artificial intelligence (AI), and especially predictive and generative AI models. These state-of-the-art technologies are leading the charge—expediting drug discovery and development, catalyzing innovation, and uncovering potential new therapies for cancer, heart disease, […]
Written by
  1. Pharmaceuticals and Drug Development

MHRA authorises enzyme inhibitor Anastrozole to prevent breast cancer in post-menopausal women

The Medicines and Healthcare products Regulatory Agency (MHRA) has today authorised this new indication for Anastrozole, a hormone treatment used for breast cancer in post-menopausal women. Anastrozole was already authorised for use in the treatment of breast cancer in post-menopausal women and has been used off-label for prevention.   Today’s announcement confirms the authorisation for […]
Written by
  1. Pharmaceuticals and Drug Development

BugBiome wins Discovery Spark life science programme

Sandwich, UK, 6th December 2023 / Discovery Park / BugBiome was announced as the winner of the Discovery Spark life science business support programme at the GIANT Health Healthcare Investment Show on 5th December. BugBiome will be awarded a business support package worth over £100,000, including one year of free lab space at Discovery Park […]
Written by
  1. Pharmaceuticals and Drug Development

New therapy that targets and destroys tau tangles is a promising future Alzheimer’s disease treatment

The team of scientists, from the Medical Research Council Laboratory of Molecular Biology (MRC LMB) in Cambridge, UK, and the UK Dementia Research Institute (UK DRI) at the University of Cambridge, say this promising approach could also be applied in future to other brain disorders driven by protein aggregation inside cells, such as motor neuron […]
Written by
  1. Pharmaceuticals and Drug Development

Innovative Trials CEO named top Woman in Pharma at the Pharma Industry Awards UK

Speaking about her win, Shaw said: “It’s truly humbling to be recognized by my peers in this way. The calibre of competition, not just for the Woman in Pharma award, but across all award categories, was exceptionally high. Congratulations to everyone who was shortlisted for a UK Pharma Industry Award and particularly all the deserving […]
Written by
  1. Pharmaceuticals and Drug Development

Three new life science start-ups thrive at Discovery Park

The new businesses are all contract research organisations, namely Biowaived, Matheus Engineering and Particology Ltd. Their launch has been supported by Pfizer’s Pharmaceutical Sciences Small Molecule (PSSM) division, with contracts for work to build their initial viability and momentum. The opportunity to establish these new businesses emerged from Pfizer’s cost realignment programme over the past […]
Written by
  1. Pharmaceuticals and Drug Development

Young Vilnius University Scientist I. Mogila Received Birnstiel Award for Breakthrough in CRISPR-Cas10 Research

“I feel great. The award recognises the CRISPR-Cas10 research I conducted during my PhD studies, investigating the bacterial defence system against viruses. I would like to thank my PhD supervisor, Dr Gintautas Tamulaitis, and the Head of the VU LSC School of Doctoral Studies, Dr Daiva Baltriukiene, for their encouragement and for nominating me for […]
Written by
  1. Pharmaceuticals and Drug Development

VU Researchers Publish Study on the Mechanism of CRISPR-Cas “Protein Scissors” in Molecular Cell

CRISPR-Cas systems help to protect bacteria from viruses. Several different types of CRISPR-Cas defense systems are found in bacteria, which differ in their composition and functions. Among them, the most studied proteins today are Cas9 and Cas12, also known as DNA or gene ‘scissors’, which have revolutionized the field of genome editing, enabling scientists to […]
Written by
  1. Pharmaceuticals and Drug Development

Pioneer Group’s life sciences campuses host biggest Ada Lovelace Day event to date

The event was the seventh annual Ada Lovelace Day celebration run by Pioneer in collaboration with educational charity Ignite! and the biggest to date. The two-day event showcased the real-world impact of women in science through interactive workshops held at MediCity Nottingham, Kent Science Park, Wilton Centre, Hexagon Tower, BioCity Glasgow, BioCity Nottingham, Edinburgh Technopole, […]
Written by
  1. Pharmaceuticals and Drug Development

Discovery Park Ventures expands fund to £3m to invest in more innovative science and technology start-ups

Sandwich, Kent, UK, 4th December 2023 – Discovery Park Ventures (DPV) announces the expansion of its early-stage life science fund from £1m to £3m, in order to capitalise on exciting investment opportunities and support its existing portfolio. The fund’s investors have committed an additional £2m, which will also enable the fund to take larger stakes […]
Written by

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.